Clinical Cardiology Alert – February 1, 2022
February 1, 2022
View Issues
-
New Treatment for Hypertrophic Obstructive Cardiomyopathy
A study of the echocardiographic characteristics of symptomatic patients with obstructive hypertrophic cardiomyopathy treated with mavacamten showed a persistent 30-week improvement in several key pathophysiologic characteristics.
-
Post-TAVR Patients with Atrial Fibrillation Bleed Less on Vitamin K Antagonists vs. Edoxaban
In this randomized trial of post-transcatheter aortic valve replacement patients with atrial fibrillation, edoxaban was noninferior to vitamin K antagonists with regard to a composite of adverse endpoints, but was associated with a higher rate of major bleeding.
-
Importance of Exercise Testing-Associated Ventricular Ectopy
A study of asymptomatic subjects without known cardiovascular disease undergoing treadmill exercise testing and followed for a mean of 20 years showed high-grade premature ventricular contractions during exercise recovery (but not during exercise) are predictive of subsequent cardiovascular mortality.
-
Jugular Venous Pressure by Bedside Ultrasound
Using a handheld point-of-care ultrasound device to estimate right atrial pressure from images of the jugular vein resulted in a higher imaging success rate vs. visual inspection and a reasonably accurate estimation, especially in those with elevated right atrial pressures.
-
Significance of Flail Mitral Leaflet and Wall-Impinging Regurgitant Flow
Using cardiac MRI as a gold standard, the presence of a flail mitral leaflet or a wall-impinging mitral regurgitant jet on transthoracic echocardiography were associated with severe mitral regurgitation, but not diagnostic of it.